Almac Diagnostic Services updates claraᵀ report with significant new content for cancer research

Almac Diagnostic Services, a member of the Almac Group, has announced significant updates to clara^T, its unique software-driven solution for gene expression data analysis, which gives cancer researchers access to the most comprehensive and robust biomarker discovery support available. 

Almac’s clara^T, which has supported over 60 oncology studies to date for multiple Biopharma and Academic clients, classifies the most biologically relevant gene expression signatures into a comprehensive easy-to-interpret report that covers all 10 Hallmarks of Cancer. 

The updates include 16 new gene expression signatures across the Hallmarks of Cancer, improved functionality with online data access and simplified reporting through an interactive dashboard.  Clients receive a unique, interactive report that allows the easy visualisation of the key discriminating biologies within either a large cohort or an individual tumour sample.

Toshimitsu Uenaka, President EPAT (Epochal Precision Anti-Cancer Therapeutics), at Eisai Inc., whose translational team have used Almac clara^T stated: “We really found the clara^T analysis of our studies to be very informative and a useful tool for our future drug discovery.”

Adding these new gene expression signatures ensures that clara^T remains current in the market with the most up to date content available. Almac clara^T offers a unique solution in the market for biomarker discovery from either RNASeq data generated from sample profiling within Almac labs or from gene expression data sets generated elsewhere that require further bioinformatics analysis.

Professor Richard Kennedy, Global VP and Medical Director, Almac Diagnostic Services said: “Being able to equip leading Biopharma and academic cancer researchers globally with a powerful gene expression analysis platform has supported the identification of exciting new data.

“Conventionally gene expression signatures are applied individually to classify patients into molecular subgroups.  Signatures designed to identify the same biology are often developed independently using different bioinformatics algorithms and therefore may not classify identically.  To address this, we developed the clara^T software solution which uses consensus between multiple published signatures, categorised into the Hallmarks of Cancer, to classify cancers in a more robust manner. Importantly, this standardised bioinformatics approach enables the analysis of datasets in a highly reproducible and cost-effective offering.

“Our proprietary clara^T report has demonstrated its ability to accelerate mRNA-based research, enabling deeper insights into translational cohorts which leads to better drug development and trial stratification, potentially contributing to better patient outcomes in the future.”

Almac Diagnostic Services is hosting a GenomeWeb Webinar on Tuesday 13^th June alongside leading cancer researchers from the University of Kansas, USA.  The webinar will focus on how clara^T was utilised effectively within breast cancer studies. 

The LIVE webinar will be held at 11am EDT / 4pm BST and interested parties can sign up here.

To find out more about Almac clara^T visit: www.almacgroup.com/diagnostics/claratreport 

ENDS

——————————————————————————————————————————–

About Almac Diagnostic Services

Your global partner for biomarker discovery, development & commercialisation.

Almac Diagnostic Services supports global pharma and biotech companies with their biomarker strategies from discovery through to companion diagnostic partnerships.

We have clinical and research laboratories in Europe and the USA, alongside strategic partnerships in China, enabling us to support global studies.

The core services we offer fall into three main categories:

• Genomic Services

• Clinical Trial Assays

• Companion Diagnostics

For more information visit: www.almacgroup.com/diagnostics

About Almac clara^T

Almac clara^T is a unique software-driven solution, classifying biologically relevant gene expression signatures into a comprehensive, easy-to-interpret report. 

clara^{T *} classifies multiple publicly available gene expression signatures and single gene targets linked to multiple key biologies, alongside Almac’s own proprietary assays, according to the 10 Hallmarks of Cancer. 

Clients are provided with a unique, interactive report that allows the easy visualisation of the key discriminating biologies within either a large cohort or an individual tumour sample. Supplementary files are also included in the report and are hyperlinked within each profile for additional data functionality.

A pan-cancer solution, based on a powerful bioinformatics pipeline, automatically generating the clara^T report from raw gene expression data utilising Almac RNA-Seq Solutions.

* Note: clara^T is for research use only (RUO) and is not to be used for diagnostic or prognostic purposes, including predicting responsiveness to a particular therapy.

About Almac Group

The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. Its innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, analytical services, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.

The international company is a privately owned organisation which has grown organically over the past five decades now employing over 6,500 highly skilled personnel across 18 facilities including Europe, the US and Asia.

To keep up to date with latest news, follow us on Twitter and LinkedIn or visit almacgroup.com